TP53 and prostate cancer: We also show, here, that in addition to well-established oncogenes such as AR and TP53, mutations in lesser studied genes such as EYA1, CSMD3, FLT4, NCOR2, and PCDH15 are enriched in prostate cancer metastases relative to primary tumors.